From the Research Center to the Clinic: Biologics and Other Systemic Therapies Part 1

In episode 48 of Derms and Conditions, our host James Q. Del Rosso, DO, sits down with Andrew Blauvelt, MD, MBA, a clinical trials investigator and former President and Owner of the Oregon Medical Research Center. Dr. Blauvelt has conducted almost 200 clinical trials on biologics and JAK inhibitors! In part 1 of this series, the two discuss the best way to learn about these new therapies for psoriasis.

With 11 biologic medications now available for psoriasis, Dr. Blauvelt recommends breaking them down into three categories based on mechanism: the original TNF blockers, the IL-17 blockers, and the IL-23 blockers. He suggests that dermatologists should have a go-to medication in each class and provides several tips on choosing the right class for the right patient based on efficacy, safety, and convenience.

Next, Dr. Del Rosso asks about the role these agents can play in affecting cardiovascular events for which psoriasis is a known risk factor. Dr. Blauvelt shares his favorite class of biologics for slowing down atherosclerosis, and recommends the best class for other common comorbidities, such as IBD, hepatitis or HIV infection, and cancer.

Finally, the two switch gears and discuss oral options for psoriasis and how deucravacitinib, recently approved by the FDA last September, fairs against other options. This episode is full of clinical pearls for managing your psoriasis patients with all the newest therapies, so tune in to learn more!